Literature DB >> 17103382

Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.

R Natrajan1, S E Little, N Sodha, J S Reis-Filho, A Mackay, K Fenwick, A Ashworth, E J Perlman, J S Dome, P E Grundy, K Pritchard-Jones, C Jones.   

Abstract

Despite aggressive salvage regimens, approximately half of all children who suffer a Wilms' tumour recurrence will die of their disease. Although there are increasing data on molecular genetic prognostic factors present in the tumour at diagnosis, there is little information regarding the molecular events that occur with Wilms' tumour progression and relapse. In the present study, microarray-based comparative genomic hybridization (aCGH) analysis has been carried out on 58 Wilms' tumour samples, which included 38 untreated primary and 20 recurrent tumours. A higher degree of copy number changes was observed in the recurrent tumours (33.0% genomic clones) than in the primary tumour (21.2%). Paired analysis highlighted the acquisition of 15q gain with high levels of IGF1R expression in the tumour recurrence in two cases. The most statistically significant abnormality acquired between diagnosis and relapse was loss of 17p. One case that experienced 17p loss was classified as favourable histology at diagnosis, but exhibited diffuse anaplasia at recurrence and had a homozygous TP53 deletion. Another instructive case with a constitutional 11p13 deletion presented with bilateral tumours and suffered two subsequent recurrences in the left kidney. A somatic WT1 mutation was found only in the right kidney tumour, while the constitutional 11p13 deletion was the only abnormality detected in the initial left kidney tumour by aCGH. The two subsequent relapses in the left kidney contained an accumulation of additional genetic alterations, including an independent WT1 mutation. Copyright (c) 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2007        PMID: 17103382     DOI: 10.1002/path.2087

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

Authors:  Elizabeth J Perlman; Paul E Grundy; James R Anderson; Lawrence J Jennings; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; E Cristy Ruteshouser; Vicki Huff
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

Review 2.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

3.  Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor.

Authors:  Ming-Ru Chiang; Chi-Wen Kuo; Wen-Chung Wang; Tai-Cheng Hou; Chen-Yun Kuo; Meng-Yao Lu; Yen-Chein Lai
Journal:  Pathol Oncol Res       Date:  2019-01-23       Impact factor: 3.201

4.  Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Authors:  Eric J Gratias; Jeffrey S Dome; Lawrence J Jennings; Yueh-Yun Chi; Jing Tian; James Anderson; Paul Grundy; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Elizabeth J Perlman
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

Review 5.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 6.  Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.

Authors:  Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Authors:  Eric J Gratias; Lawrence J Jennings; James R Anderson; Jeffrey S Dome; Paul Grundy; Elizabeth J Perlman
Journal:  Cancer       Date:  2013-08-26       Impact factor: 6.860

Review 8.  Wilms' tumor: biology, diagnosis and treatment.

Authors:  Elwira Szychot; John Apps; Kathy Pritchard-Jones
Journal:  Transl Pediatr       Date:  2014-01

Review 9.  Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade.

Authors:  Li Zhou; Daniel Catchpoole
Journal:  Transl Pediatr       Date:  2015-04

10.  Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Authors:  Kylie M Drake; E Cristy Ruteshouser; Rachael Natrajan; Phyllis Harbor; Jenny Wegert; Manfred Gessler; Kathy Pritchard-Jones; Paul Grundy; Jeffrey Dome; Vicki Huff; Chris Jones; Micheala A Aldred
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.